文献速递泌尿男性生殖肿瘤乳腺癌

类固醇生成抑制剂ODM-209治疗转移性去势抵抗性前列腺癌和晚期乳腺癌:首次人体STESIDES研究结果

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
PubMed 文献 · Eur J Cancer · 2026-09-12

STESIDES是一项首次人体剂量探索研究,评估口服CYP11A1抑制剂ODM-209在转移性去势抵抗性前列腺癌(mCRPC)和晚期乳腺癌(aBC)患者中的安全性和活性。38例患者接受ODM-209 10-20 mg/天治疗,所有患者出现不良事件,疲劳(53%)和外周水肿(34%)最常见。10例(29%)mCRPC患者PSA下降≥50%,尤其携带AR-LBD突变者PSA50反应率为47%(9/19),aBC患者未见缓解。

要点

  • ODM-209在经重度治疗的mCRPC中显示活性,尤其携带AR-LBD突变者。
  • 常见不良事件为疲劳(53%)和外周水肿(34%),3例(8%)发生严重肾上腺功能不全事件。
  • aBC患者未见临床缓解,需进一步探索其他治疗策略。

核心结论

  • ODM-209在经重度治疗的mCRPC患者中显示抗肿瘤活性,尤其携带活化性AR-LBD突变者,不良事件谱符合预期。

研究设计与样本

  • STESIDES为首次人体剂量探索研究(3+3设计),纳入进展性mCRPC患者(接受过≥1种AR通路抑制剂和≥1种紫杉类方案)及aBC患者,ODM-209口服给药并联合糖皮质激素和盐皮质激素替代治疗。

主要发现

  • 38例患者接受ODM-209(mCRPC 34例,aBC 4例),剂量范围10-20 mg/天;所有患者出现不良事件,疲劳(53%)和外周水肿(34%)最常见。
  • 9例(24%)发生与ODM-209相关的≥3级不良事件;3例(8%)发生严重肾上腺功能不全事件,其中1例为DLT(aBC患者)。
  • 治疗期间类固醇激素浓度大多检测不到。
  • 10例(29%)mCRPC患者PSA下降≥50%(PSA50),包括携带AR-LBD突变者;该突变亚组PSA50反应率为47%(9/19),中位治疗持续时间5.6个月。
  • 16例可评估mCRPC患者中3例(19%)达到部分临床缓解;aBC患者未见缓解。

关键数值与推荐

  • mCRPC患者PSA50反应率:总体10/34(29%),AR-LBD突变亚组9/19(47%)。
  • 可评估mCRPC患者部分临床缓解率:3/16(19%)。
  • ≥3级ODM-209相关不良事件发生率:9/38(24%);严重肾上腺功能不全事件发生率:3/38(8%)。

临床怎么用

  • 对于经AR通路抑制剂和紫杉类治疗失败的mCRPC患者,尤其携带AR-LBD突变者,ODM-209可能是一种有前景的选择。
  • 治疗期间需监测肾上腺功能不全,并常规联合糖皮质激素和盐皮质激素替代治疗。
  • aBC患者未观察到临床缓解,不推荐在未经选择的人群中使用。

局限性

  • 样本量小(38例),尤其aBC仅4例,结论受限。
  • 为剂量探索研究,未设对照,疗效需进一步验证。
  • 随访时间及长期安全性数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer (aBC) have poor outcomes with standard treatments. We report phase 1 results from the STESIDES (NCT03878823) study of ODM-209, an oral selective CYP11A1 inhibitor that blocks all synthesis of steroid hormones. METHODS: STESIDES was a dose-finding study (3 +3 design) in adults with progressive mCRPC, with or without activating androgen receptor ligand-binding domain (AR-LBD) mutations, who received ≥ 1 prior AR pathway inhibitor and ≥ 1 taxane-based regimen. Participants with aBC were also enrolled. ODM-209 was administered with glucocorticoid and mineralocorticoid replacement therapy. Primary endpoints included dose-limiting toxicities (DLTs) and adverse events (AEs); secondary endpoints included pharmacodynamics and clinical response. RESULTS: Thirty-eight participants received ODM-209 (mCRPC: 34; aBC: 4); dose range: 10-20 mg/day. All experienced AEs; fatigue (53%) and peripheral edema (34%) were most common. Nine (24%) experienced grade ≥ 3 AEs related to ODM-209. Three (8%) had serious adrenal insufficiency events (including terms adrenal insufficiency, glucocorticoid deficiency and adrenocortical insufficiency acute); one was a DLT (participant with aBC). Steroid hormone concentrations were mostly undetectable upon treatment. Ten (29%) participants with mCRPC had prostate-specific antigen decline ≥ 50% (PSA50), including patients with AR-LBD mutations (PSA50 response rate: 9/19 [47%]; 5.6-month median treatment duration for this group). Three of 16 (19%) evaluable participants with mCRPC had partial clinical response. No responses were seen in participants with aBC. CONCLUSIONS: ODM-209 showed activity in heavily pretreated participants with mCRPC, particularly those with activating AR-LBD mutations, with an expected AE profile.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bernard-Tessier A, Spanggaard I, Utriainen T, et al. Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study. Eur J Cancer. 2026. PMID: 42777289. doi:10.1016/j.ejca.2026.117041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。